P. Cassier

Pembrolizumab in Microsatellite Instability High or Mismatch Repair Deficient Cancers: Updated Analysis from the Phase 2 KEYNOTE-158 Study.

P. Ascierto, W. Miller, A. Marabelle, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high/mismatch repair deficient endometrial cancer in the KEYNOTE-158 study.

M. Amonkar, A. Hansen, A. Marabelle, 2022, Gynecologic oncology.

A phase 1b study of crenigacestat (LY3039478) in combination with gemcitabine and cisplatin or gemcitabine and carboplatin in patients with advanced or metastatic solid tumors

C. Massard, K. Benhadji, S. Pant, 2022, Cancer Chemotherapy and Pharmacology.

A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma.

J. Ware, N. Tunariu, H. Koeppen, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SO-8 Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair deficient advanced solid tumors: Results from the KEYNOTE-158 study

P. Ascierto, W. Miller, M. Maio, 2021, Annals of Oncology.

983P Phase I dose escalation study in patients (pts) with advanced solid tumours receiving first-in-class BI 765063, a selective signal-regulatory protein α (SIRPα) inhibitor, in combination with ezabenlimab (BI 754091), a programmed cell death protein 1 (PD-1) inhibitor

S. Champiat, A. Marabelle, J. Delord, 2021, Annals of Oncology.

A phase I dose escalation trial evaluating the impact of an in situ immunization strategy with intra-tumoral injections of Pexa-Vec in combination with ipilimumab in advanced solid tumors with injectable lesions

F. Pilleul, C. Caux, D. Pérol, 2018, Annals of Oncology.

LBA12 Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial

M. Millward, C. Ferté, Chiung-Ying Liao, 2022, Annals of Oncology.

MA06.03 KontRASt-01: Preliminary Safety and Efficacy of JDQ443 + TNO155 in Patients with Advanced, KRAS G12C-Mutated Solid Tumors

A. Farago, P. Cassier, C. Dooms, 2023, Journal of Thoracic Oncology.